Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation

Franca, Juçara Ribeiro; Foureaux, Giselle; Fuscaldi, Leonardo Lima; Ribeiro, Tatiana G.; Castilho, Rachel Oliveira; Yoshida, María Irene; Cardoso, Valbert Nascimento; Fernandes, Simone Odília Antunes; Cronemberger, Sebastião; Nogueira, José Carlos; Ferreira, Anderson J.; Faraco, André Augusto Gomes

doi:10.1016/j.ijpharm.2019.118662

Cited by 45 publications

(23 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared to eye drops, biodistribution studies with radiolabeled drugs revealed significantly more diminazene aceturate in the ocular region and significantly less in the gastrointestinal tract. The same team, again for glaucoma treatment, prepared membranes of CS and hydroxyethyl cellulose loaded with dorzolamide [ 280 ]. Dorzolamide was molecularly dispersed within the polymeric matrix, and the formation of hydrogen bonds was evidenced.…”

Section: Ocular Lenses and Insertsmentioning

confidence: 99%

Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments

et al. 2020

View full text Add to dashboard Cite

Chitosan (CS) is a hemi-synthetic cationic linear polysaccharide produced by the deacetylation of chitin. CS is non-toxic, highly biocompatible, and biodegradable, and it has a low immunogenicity. Additionally, CS has inherent antibacterial properties and a mucoadhesive character and can disrupt epithelial tight junctions, thus acting as a permeability enhancer. As such, CS and its derivatives are well-suited for the challenging field of ocular drug delivery. In the present review article, we will discuss the properties of CS that contribute to its successful application in ocular delivery before reviewing the latest advances in the use of CS for the development of novel ophthalmic delivery systems. Colloidal nanocarriers (nanoparticles, micelles, liposomes) will be presented, followed by CS gels and lenses and ocular inserts. Finally, instances of CS coatings, aiming at conferring mucoadhesiveness to other matrixes, will be presented.

show abstract

Section: Ocular Lenses and Insertsmentioning

confidence: 99%

Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Okuläre Inserte nur mit CS werden für verschiedene Wirkstoffe zur Glaukombehandlung entwickelt, z.B. für Bimatoprost [212], Brimonidintartarat [213] und Diminazen [214], außerdem in Kombination mit Hydroxyethylcellulose für Dorzolamid [215] und in Kombination zu gleichen Teilen mit Chondroitinsulfat für Diminazen [216].…”

Section: Neuartige Wirkstoffabgabesystemeunclassified

Neuartige Wirkstoffabgabesysteme für die Glaukomtherapie: Hürden und Lösungsansätze für die Formulierung

et al. 2021

View full text Add to dashboard Cite

Das Glaukom gilt als eins der größten gesundheitlichen Probleme weltweit. Es ist die häufigste vermeidbare Erblindungsursache – zum Einen, weil es in der Frühphase asymptomatisch bleibt, zum Anderen wegen mangelnder Therapietreue der Patienten. Es gibt bei der Behandlung des Glaukoms verschiedene Herangehensweisen, die jeweils auf den Einzelfall abgestimmt werden müssen. Die erste Therapielinie ist eine medikamentöse Behandlung. Da jedoch die herkömmlichen Darreichungsformen zahlreiche Nachteile aufweisen, wird intensiv an der Entwicklung neuartiger Wirkstoffabgabesysteme für die Glaukomtherapie gearbeitet. Die vorliegende Übersichtsarbeit gibt einen Überblick über Lösungsansätze und Strategien bei der Entwicklung von Darreichungsformen wie in situ gelierenden Systemen, Nanosystemen, okulären Inserten, Kontaktlinsen, Cornea Shields aus Kollagen, okulären Implantaten, Mikronadeln und Iontophoresesystemen. Ergänzend werden Ergebnisse von Studien zur Wirksamkeit dieser Wirkstoffabgabesysteme kurz vorgestellt.

show abstract

“…Ocular inserts with CS alone are being developed for various antiglaucoma drugs, such as bimatoprost [212], brimonidine tartarate [213], diminazene [214], in a combination with hydroxyethyl cellulose for dorzolamide [215] or in a combination of equal parts with chondroitin sulfate for diminazene [216].…”

Section: Ocular Insertsmentioning

confidence: 99%

Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions

et al. 2020

View full text Add to dashboard Cite

Glaucoma is considered to be one of the biggest health problems in the world. It is the main cause of preventable blindness due to its asymptomatic nature in the early stages on the one hand and patients’ non-adherence on the other. There are several approaches in glaucoma treatment, whereby this has to be individually designed for each patient. The first-line treatment is medication therapy. However, taking into account numerous disadvantages of conventional ophthalmic dosage forms, intensive work has been carried out on the development of novel drug delivery systems for glaucoma. This review aims to provide an overview of formulation solutions and strategies in the development of in situ gel systems, nanosystems, ocular inserts, contact lenses, collagen corneal shields, ocular implants, microneedles, and iontophoretic devices. The results of studies confirming the effectiveness of the aforementioned drug delivery systems were also briefly presented.

show abstract

Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation

Cited by 45 publications

References 45 publications

Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments

Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments

Neuartige Wirkstoffabgabesysteme für die Glaukomtherapie: Hürden und Lösungsansätze für die Formulierung

Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions

Contact Info

Product

Resources

About